PROTACs are promising candidates because of selective protein degradation, including Aβ and tau characteristics in the pathology of AD, α-synuclein characteristics in the pathology of PD, and huntingtin characteristics in the pathology of HD. This evidence concerns the gene MAPT and Huntington disease.